Navigation Links
Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
Date:1/12/2010

CHARLOTTESVILLE, Virginia, January 12 /PRNewswire/ -- Biovista Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects.

The FDA's Office of Clinical Pharmacology, within the Center for Drug Evaluation and Research (CDER), will test the use of Biovista's Adverse Event Analysis (AEA) technology and work closely with Biovista scientists to carefully study the serious side effects of several drugs or classes of drugs, identified by FDA, to help promote safer use of these medications. The goal of the collaboration is to explore the possibility of being able to predict which patients may be most likely to experience adverse reactions to these medications so that healthcare providers can better protect their safety.

"We look forward to working with Biovista and using its technology platform which may help reduce risks associated with using certain medications and help improve how healthcare providers go about selecting the drugs they prescribe for their patients," said Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology at CDER. "This license is an example of how FDA hopes to work with leading-edge technologies and collaborators to meet the goals of the agency's Safe Use Initiative."

"We are very pleased to collaborate with FDA in the analysis of drug side effects, using our AEA technology. CDER's Office of Clinical Pharmacology has a track record of innovation. We believe FDA's new Safe Use Initiative is a natural fit for our unique AEA technology, and we look forward to working closely with FDA and potentially helping to improve the safe use of drug products," said Aris Persidis, Ph.D., President of Biovista Inc.

About Biovista's Adverse Event Analysis technology

Biovista's AEA technology forms part of the company's Clinical Outcomes Search Space (COSS(tm)) platform that focuses on mechanism of action-based correlations between drugs, disease efficacy and adverse events. The AEA technology cross-correlates over 8,000 diseases and 12,000 adverse events known to medicine against any target, drug or combination. This enables researchers to link pre-clinical experimental data directly with potential clinical outcomes, and to explore the possible risks of adverse events from a mechanistic perspective. It also helps researchers explain adverse events after these occur, in cases where these events were unexpected or not monitored for during trials, and to differentiate the causes of adverse events among a drug or the underlying disease.

About the Safe Use Initiative

The goal of FDA's Safe Use Initiative is to reduce preventable harm by identifying specific, preventable medication risks and developing, implementing and evaluating cross-sector interventions with partners who are committed to safe medication use.

    For more information, please contact:

    Dr. Aris Persidis
    Biovista, Inc.
    arisp@biovista.com
    +1-434-242-6514

SOURCE Biovista Inc.


'/>"/>
SOURCE Biovista Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biovista Inc. Named Top Innovator in Life Sciences
2. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
3. The ZigBee Alliance and Continua Health Alliance Collaborate to Expand Telehealth Capabilities
4. Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat
5. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
8. febit and TGen Collaborate to Study New DNA Capture Method
9. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... June 1, 2017 Nutriceutical Holdings (NH), parent ... Solutions (VRS), and KD Pharma Group have decided to ... by KD Pharma Group. KD Pharma Group will become ... to acquire the entire company. "We believe ... are committed to growing the NH companies by providing ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
Breaking Medicine Technology:
(Date:6/24/2017)... , ... June 24, 2017 , ... The weather is ... time outdoors. Home and business owners should be aware that the summer months provide ... In fact, mechanical locks and keys can be negatively affected from direct exposure to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... , ... June 23, 2017 , ... By scoring 100% ... ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work ... 1% of all charities reviewed by Charity Navigator and earns ANRF a spot on ...
(Date:6/23/2017)... , ... June 24, 2017 , ... Studies show evidence ... reduce the risk of visual loss in these patients. , But how often do ... or smoking cessation to patients at risk of or with early symptoms of AMD? ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
Breaking Medicine News(10 mins):